- Home
- PHAR vs MMI Comparison
PHAR vs MMI Comparison
Compare PHAR & MMI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PHAR | MMI |
|---|---|---|
| Founded | 1988 | 1971 |
| Country | Netherlands | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.2B |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | PHAR | MMI |
|---|---|---|
| Price | $16.79 | $25.53 |
| Analyst Decision | Strong Buy | Sell |
| Analyst Count | 2 | 2 |
| Target Price | ★ $38.00 | $28.00 |
| AVG Volume (30 Days) | 34.2K | ★ 271.5K |
| Earning Date | 03-12-2026 | 02-13-2026 |
| Dividend Yield | N/A | ★ 1.99% |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.00 | N/A |
| Revenue | $362,274,000.00 | ★ $751,284,000.00 |
| Revenue This Year | $25.19 | $11.08 |
| Revenue Next Year | $4.47 | $15.63 |
| P/E Ratio | $3,082.88 | ★ N/A |
| Revenue Growth | ★ 26.78 | 20.74 |
| 52 Week Low | $7.50 | $24.99 |
| 52 Week High | $21.34 | $41.94 |
Technical Indicators
Market Signals| Indicator | PHAR | MMI |
|---|---|---|
| Relative Strength Index (RSI) | 40.82 | 38.64 |
| Support Level | $16.30 | $26.13 |
| Resistance Level | $18.03 | $27.49 |
| Average True Range (ATR) | 0.73 | 0.83 |
| MACD | -0.35 | -0.06 |
| Stochastic Oscillator | 9.72 | 19.31 |
Price Performance
Historical ComparisonAbout PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
About MMI Marcus & Millichap Inc.
Marcus & Millichap Inc is a national brokerage firm specializing in commercial real estate investment sales, financing, research, and advisory services. The company offers three primary services to its clients: commercial real estate investment brokerage, financing, and ancillary services, including other research, advisory, and consulting services. The company generates revenues by collecting fees on the sale and financing of commercial properties. These fees consist of commissions collected upon the sale of a property and fees collected from the placement of loans.